이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pliant Therapeutics 배당금

배당금 기준 확인 0/6

Pliant Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.2%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$3.05
배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Sep 13

Pliant Therapeutics: Good Data, But Will Need Watching

Sep 11

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 PLRX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: PLRX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Pliant Therapeutics 시장 대비 배당 수익률

PLRX 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (PLRX)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Pharmaceuticals)	2.2%
애널리스트 예측 (PLRX) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PLRX 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PLRX 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PLRX 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: PLRX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Pliant Therapeutics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Pliant Therapeutics: Good Data, But Will Need Watching

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 69%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.1% to US$42.67

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$44.08

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings released: US$0.69 loss per share (vs US$0.65 loss in 3Q 2022)

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Consensus revenue estimates fall by 32%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Business Officer notifies of intention to sell stock

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 123%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel & Corporate Secretary notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

President notifies of intention to sell stock

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Price target increased by 17% to US$49.09

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

President notifies of intention to sell stock

Insufficient new directors

General Counsel & Corporate Secretary notifies of intention to sell stock

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options and sold US$256k worth of stock

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics: Wait For A Better Price To Get In

Consensus revenue estimates increase by 48%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant's PLN-74809 gets FDA fast track status for liver disease

Price target increased to US$43.71

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant: Major Catalyst Expected Beginning Of 2023

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

Price target decreased to US$39.67

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers

Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis